Drug Database
ZO

zolpidem tartrate (Stilnox CR / FK199B / Stilnoxium)

✓ Approved

Astellas Pharma · GABRA1 · Small Molecule

What is zolpidem tartrate?

zolpidem tartrate is a small molecule developed by Astellas Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesStilnox CR, FK199B, Stilnoxium
CompanyAstellas Pharma
Drug ClassSmall Molecule
Molecular TargetGABRA1
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

zolpidem tartrate acts on 1 molecular target:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (DEE19, ECA4)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

zolpidem tartrate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersInsomnia✓ Approved

Related Research Articles

PubMedBiomechanics and modeling in mechanobiology2026-09-20

Multiscale model calibrated with a Bayesian algorithm predicts long-term outcomes of treatments for mitral valve regurgitation in animal models.

Bracamonte Johane H JH, Watkins Lionel L, Saucerman Jeffrey J JJ, Holmes Jeffrey W JW

In primary mitral valve regurgitation (MR), a failing valve induces volume overload (VO) of the left ventricle (LV), triggering neurohormonal responses and myocardial remodeling. Surgical valve repair is the most effective therapy for MR, improving symptoms and in some patients reversing cardiac hypertrophy. However, at least 20% of patients develop postoperative impairment of LV function with detrimental effects on long-term outcomes, with no known cause. Many MR patients receive pharmacological treatment to alleviate symptoms, with drugs that alter cardiac function, hemodynamics, and molecular pathways that influence cardiac remodeling. To support the advancement of medical management of MR, we developed a multiscale model of cardiac hypertrophy that links ventricular mechanics, cardiovascular hemodynamics, and cardiomyocyte molecular signaling. We calibrated the model using the Markov chain Monte Carlo algorithm, a machine learning method, to integrate data from 76 studies of experimental VO in animals. The model's predictions showed good agreement with experimental data on MR in dogs, including the chronic effects of four drugs on MR-induced hypertrophy. When simulating valve repair, our model suggests that full reversal of LV hypertrophy requires both the mechanical elimination of VO and the restoration of normal neurohormonal receptor activity. Finally, we explored selecting subsets of a large pool of pre-computed simulations to personalize model predictions for a small population or individual where insufficient data are available to refit the entire model.

PubMedQuarterly journal of experimental psychology (2006)2026-09-19

EXPRESS: The Critical Role of Spatial Working Memory in Mental Rotation: Evidence from a Dual-Task Paradigm.

Liu Yushu Y, Zhang Jie J, Zhao Binglei B

Shared neural mechanisms underlie working memory (WM) and visual mental imagery (VMI) processes, yet their functional relationship remains debated, particularly regarding the contributions of visual and spatial WM to VMI. The present study employed a dual-task paradigm in which participants first maintained either visual (VWM) or spatial (SWM) information under varying memory loads (low vs. high), and subsequently performed mental rotation (MR) trials with different rotation angles. Consistent with the literature, a main effect of rotation angle on MR performance was observed, confirming the engagement of MR processes in both conditions (SWM-MR and VWM-MR). Notably, when participants were required to retain spatial information, MR accuracy was reduced in the SWM-MR condition. In contrast, no comparable impairment was observed in the VWM-MR condition. These findings suggest that MR task performance in the present paradigm is more vulnerable to concurrent spatial than visual working-memory demands, thereby helping to clarify the relationship between WM and VMI.

PubMedMedicine2026-09-19

The causal associations between 25(OH) vitamin D levels and ectopic pregnancy: A 2-sample Mendelian randomization study.

Zhang Pei-Jin PJ, Bo Shao S, Liang Shuang S, Zhang Hong-Yuan HY et al.

Previous research has indicated a potential link between 25-hydroxyvitamin D [25(OH)D] and ectopic pregnancy (EP), but the underlying causal relationship remains unclear. We performed a 2-sample Mendelian randomization (MR) study to investigate the causal association between circulating 25(OH)D and ectopic pregnancy (EP). The primary analysis used summary statistics from a 25(OH)D GWAS of 4,96,946 European-ancestry participants and FinnGen summary statistics for EP (3111 cases and 89,340 controls). To assess whether the finding was robust to the choice of 25(OH)D GWAS, we repeated the MR analysis using a separate 25(OH)D GWAS (n = 4,41,291 European-ancestry participants) as a replication analysis; it was not used solely as a within-analysis sensitivity test. The primary and replication analyses used inverse-variance weighting (IVW) as the main method, complemented by weighted mode, simple mode, weighted median, and MR-Egger analyses. Heterogeneity and pleiotropy assessments, leave-one-out analyses, and other sensitivity analyses were conducted within each MR analysis. IVW estimates showed that increased serum 25(OH)D levels promoted EP (OR = 1.323, 95% CI = 1.024-1.710, P = .032). The replication analysis also revealed similar trends (OR = 1.383, 95% CI = 1.041-1.836, P = .025). The primary and replicated analyses were combined in a meta-analysis, and the result showed a significant causal influence (OR = 1.350, 95% CI = 1.116-1.632, P = .002). Sensitivity analysis confirmed the robustness of the MR estimations. In this MR study of European-ancestry participants, genetically predicted higher circulating 25(OH)D levels were associated with a higher risk of EP. These findings do not establish serum 25(OH)D as a diagnostic marker for EP. Rather, if confirmed in further clinical studies, elevated vitamin D may be considered a potential associated risk factor only in the context of established clinical signs and symptoms of EP.

PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-09-19

Genetically supported targets and drug repurposing for sleep disorders: a Mendelian randomization systematic study.

Wang Ziyuan Z, Zhang Miao M, Liu Cong C, Zhang Yiyin Y et al.

Sleep disorders present major public health issues because of their associations with chronic diseases. Despite extensive research efforts, the underlying biological mechanisms remain inadequately understood. We performed bidirectional two-sample Mendelian randomization (MR) to investigate relationships between sleep disorders and common brain diseases, followed by summary-data-based Mendelian randomization (SMR), heterogeneity in dependent instruments (HEIDI), and colocalization analyses integrating protein quantitative trait locus (pQTL) and expression quantitative trait locus (eQTL) data to prioritize genetically supported candidate genes. Compound-gene associations were subsequently evaluated, and selected clinically used compounds underwent exploratory molecular docking and molecular dynamics simulation. Two-step MR mediation analyses and MR phenome-wide association study (MR-PheWAS) were used to investigate potential mediating traits and broader phenotypic associations. Multi-omic genetic analyses prioritized six candidate genes-BCAN, HDGF, MEPE, PAM, PRR4, and IGLON5-with BCAN, HDGF, and MEPE showing the strongest genetic support. Compound prioritization retained four clinically used drugs associated with the candidate genes for structure-based assessment. Exploratory molecular docking yielded the most favorable predicted Vina score for the BCAN-danazol pair, and molecular dynamics simulation showed persistent local BCAN-danazol contacts despite substantial global conformational rearrangement of BCAN during the trajectory. Mediation analyses identified several risk factors, cerebrospinal fluid metabolites, and structural connectivity measures showing statistical evidence consistent with partial mediation of selected gene/protein-sleep disorder associations. MR-PheWAS further characterized broader phenotypic associations of the genetically supported genes. Integrating genetic and multi-omic evidence identified candidate molecular targets and compound-gene associations relevant to sleep disorders. These findings provide hypotheses for subsequent functional and pharmacological validation.

PubMedJACC. Asia2026-09-19

Acute Valve Syndrome in Patients With Primary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.

Miyahara Daisuke D, Izumo Masaki M, Kuwata Shingo S, Okuno Taishi T et al.

Acute or advanced valve syndrome (AVS), originally proposed in aortic stenosis to describe rapid clinical deterioration, has not been evaluated in mitral regurgitation (MR). This study sought to investigate the prognostic impact of AVS in patients with primary MR undergoing mitral transcatheter edge-to-edge repair (M-TEER). We analyzed 961 patients with primary MR enrolled in the multicenter OCEAN-Mitral registry who underwent M-TEER. AVS was defined as the presence of one or more acute or advanced signs of MR, including NYHA functional class Ⅲ-Ⅳ, left ventricular ejection fraction (LVEF) <50%, elevated B-type natriuretic peptide, atrial fibrillation, hypotension, or inotropic drug use before M-TEER. Progressive valve syndrome (PVS) was defined as the absence of these signs. The primary outcome was a composite of all-cause death and heart failure hospitalization over 2 years. AVS was present in 804 patients (83.7%). These patients had more comorbidities and lower LVEF than the PVS group. Despite comparable procedural success and symptomatic improvement in both groups, event-free survival during a median follow-up of 400 (232-731) days was significantly lower in the AVS group (P < 0.001). Multivariable analysis identified AVS as an independent predictor of the composite endpoints (HR: 2.236; 95% CI: 1.105-4.415; P = 0.023). Although M-TEER yields favorable procedural and symptom outcomes in both PVS and AVS, AVS was independently associated with worse prognosis in patients with primary MR. These findings suggest that early intervention, before the development of AVS, may be beneficial. The OCEAN-Mitral trial is registered with the University Hospital Medical Information Network (UMIN000023653).

PubMedMedicine2026-09-19

Causal relationship between metabolites, cerebral volume, and amyotrophic lateral sclerosis: A 2-step Mendelian randomization analysis.

Liu Youjia Y, Chen Sihui S, Wu Yanyun Y, Zhou Wenting W et al.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motor neuron degeneration. Although metabolic abnormalities have been implicated in ALS, the causal relationships between circulating metabolites and ALS remain unclear. This study aimed to investigate the potential causal associations between plasma metabolites and ALS risk and to explore the mediating role of cerebral volume. A 2-sample Mendelian randomization (MR) study was conducted using publicly available genome-wide association study summary statistics. Genetic instruments for plasma metabolites were obtained from metabolomic GWAS datasets, and ALS-associated genetic data were used as the outcome. The inverse-variance weighted method was used as the primary analysis, with sensitivity analyses performed using MR-Egger regression, weighted median analysis, MR-PRESSO, heterogeneity testing, and leave-one-out analysis. A 2-step MR analysis was further conducted to evaluate whether cerebral volume mediated the associations between metabolites and ALS. Six metabolites showed significant associations with ALS risk. Genetically predicted higher levels of N,N-dimethylalanine, Behenylcarnitine (C22), and deoxycarnitine were associated with increased ALS risk, whereas higher levels of (N(1) + N(8))-acetylspermidine, Betaine, and tetradecadienedioate (C14:2-DC) were associated with decreased ALS risk. Sensitivity analyses supported the robustness of the findings. Two-step MR analysis suggested that cerebral volume did not significantly mediate the associations between these metabolites and ALS risk. This study identified 6 circulating metabolites genetically associated with ALS risk. These findings provide insights into the potential metabolic pathways involved in ALS and suggest that the observed associations are unlikely to be mediated through cerebral volume changes.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about zolpidem tartrate